These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 34480615)

  • 1. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
    Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
    Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation.
    Zhou JR; Shi DY; Wei R; Wang Y; Yan CH; Zhang XH; Xu LP; Liu KY; Huang XJ; Sun YQ
    Front Immunol; 2020; 11():620891. PubMed ID: 33664733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical Study of Allogeneic Hematopoietic Stem Cell Transplantation Patients with Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus].
    Wang ZW; Liu Q; Sun HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):561-567. PubMed ID: 38660867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Features of Epstein-Barr Virus and Cytomegalovirus Reactivation in Acute Leukemia Patients After Haplo-HCT With Myeloablative ATG-Containing Conditioning Regimen.
    Ru Y; Zhu J; Song T; Ding Y; Zhu Z; Fan Y; Xu Y; Sun A; Qiu H; Jin Z; Tang X; Han Y; Fu C; Chen S; Ma X; Chen F; Chen J; Wu D
    Front Cell Infect Microbiol; 2022; 12():865170. PubMed ID: 35651756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.
    Ke P; Zhang X; Liu S; Zhu Q; Ma X; Chen F; Tang X; Han Y; Fu Z; Chen S; Wu D; Qiu H; Zhou J; Bao X
    Ann Hematol; 2021 Jul; 100(7):1879-1889. PubMed ID: 33885923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.
    Xuan L; Huang F; Fan Z; Zhou H; Zhang X; Yu G; Zhang Y; Liu C; Sun J; Liu Q
    J Hematol Oncol; 2012 Aug; 5():46. PubMed ID: 22856463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Cytomegalovirus and Epstein-Barr Virus Co-Reactivation and Hematopoietic Stem Cell Transplantation.
    Li SS; Zhang N; Jia M; Su M
    Front Cell Infect Microbiol; 2022; 12():818167. PubMed ID: 35402291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation.
    Hu J; Zhao J; Wang C; Jia M; Su M; Li S
    Ann Hematol; 2023 Dec; 102(12):3593-3601. PubMed ID: 37831153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical outcomes of allogeneic hematopoietic stem cell transplantation patients with co-activation of cytomegalovirus and Epstein-Barr virus].
    Song T; Chen G; Zhang X; Xu Y; Chen J; Wang Y; Ye L; Xu J; Wu D; Miao J
    Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3135-9. PubMed ID: 25573307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-α/β- and CD19-Depleted Grafts.
    Laberko A; Bogoyavlenskaya A; Shelikhova L; Shekhovtsova Z; Balashov D; Voronin K; Kurnikova E; Boyakova E; Raykina E; Brilliantova V; Pirumova V; Novichkova G; Maschan A; Maschan M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):483-490. PubMed ID: 28039080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
    Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
    Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation.
    Huang J; Pan Z; Wang L; Zhang Z; Huang J; Jiang C; Cai G; Yin T
    Clin Exp Med; 2024 Jan; 24(1):22. PubMed ID: 38280072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Reactivation of Cytomegalovirus and Epstein-Barr Virus in Patients with B Cell Lymphoma.
    Hatayama Y; Watanabe K; Ichikawa H; Kawamura K; Fukuda T; Motokura T
    Viral Immunol; 2023 Oct; 36(8):520-525. PubMed ID: 37440168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial.
    Xu X; Fan Z; Wang Y; Huang F; Xu Y; Sun J; Xu N; Deng L; Li X; Liang X; Luo X; Shi P; Liu H; Chen Y; Tu S; Huang X; Liu Q; Xuan L
    BMC Med; 2022 Sep; 20(1):282. PubMed ID: 36050712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation.
    Jaskula E; Dlubek D; Sedzimirska M; Duda D; Tarnowska A; Lange A
    Transplant Proc; 2010 Oct; 42(8):3273-6. PubMed ID: 20970670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
    Ghobadi A; Milton DR; Gowda L; Rondon G; Chemaly RF; Hamdi A; Alousi A; Afrough A; Oran B; Ciurea S; Kebriaei P; Popat UR; Qazilbash MH; Shpall EJ; Champlin RE; Bashir Q
    Curr Res Transl Med; 2019 May; 67(2):51-55. PubMed ID: 30683577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.